DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Saura C, Oliveira M, Feng YH, Dai MS, Hurvitz SA, Kim SB.
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.
J Clin Oncol 2019;
37: 1002
Access:
We do not assume any responsibility for the contents of the web pages of other providers.